tiprankstipranks
Advertisement
Advertisement

CH:BIIB Stock Latest News

Stoke Therapeutics, Biogen present long-term data on Zorevunersen
The FlyStoke Therapeutics, Biogen present long-term data on Zorevunersen
3d ago
BIIB
STOK
Biogen price target raised to $245 from $225 at Piper Sandler
PremiumThe Fly
Biogen price target raised to $245 from $225 at Piper Sandler
4d ago
BIIB
Biogen, Eisai announce NMPA of China approves subcutaneous Leqembi
PremiumThe Fly
Biogen, Eisai announce NMPA of China approves subcutaneous Leqembi
4d ago
BIIB
Stoke Therapeutics, Biogen present clinical data of Dravet syndrome candidate
PremiumThe Fly
Stoke Therapeutics, Biogen present clinical data of Dravet syndrome candidate
6d ago
BIIB
STOK
Biogen, Eisai announce positive recommendation for Leqembi in Canada
PremiumThe Fly
Biogen, Eisai announce positive recommendation for Leqembi in Canada
7d ago
BIIB
Veeva price target raised to $310 from $270 at Needham
PremiumThe FlyVeeva price target raised to $310 from $270 at Needham
11d ago
LLY
BIIB
Biogen price target raised to $260 from $240 at RBC Capital
Premium
The Fly
Biogen price target raised to $260 from $240 at RBC Capital
13d ago
BIIB
Eisai, Biogen announces once weekly lecanemab-irmb availability in the U.S.
Premium
The Fly
Eisai, Biogen announces once weekly lecanemab-irmb availability in the U.S.
14d ago
BIIB
Biogen, Eisai announce Leqembi Iqlik now available in U.S.
PremiumThe Fly
Biogen, Eisai announce Leqembi Iqlik now available in U.S.
14d ago
BIIB
ProMIS Neurosciences price target lowered to $29 from $30 at Roth Capital
PremiumThe Fly
ProMIS Neurosciences price target lowered to $29 from $30 at Roth Capital
17d ago
PMN
BIIB
Biogen upgraded to Outperform from Peer Perform at Wolfe Research
PremiumThe Fly
Biogen upgraded to Outperform from Peer Perform at Wolfe Research
21d ago
BIIB
Wolfe upgrades Biogen to Outperform on late-stage pipeline
PremiumThe Fly
Wolfe upgrades Biogen to Outperform on late-stage pipeline
21d ago
BIIB
Five Below upgraded, StubHub downgraded: Wall Street’s top analyst calls
PremiumThe FlyFive Below upgraded, StubHub downgraded: Wall Street’s top analyst calls
21d ago
OI
ALC
Biogen completes acquisition of RayThera
Premium
The Fly
Biogen completes acquisition of RayThera
1M ago
BIIB
Biogen price target raised to $241 from $221 at Mizuho
Premium
The Fly
Biogen price target raised to $241 from $221 at Mizuho
1M ago
BIIB
Biogen price target raised to $215 from $200 at Citi
PremiumThe Fly
Biogen price target raised to $215 from $200 at Citi
1M ago
BIIB
Biogen price target raised to $231 from $222 at Morgan Stanley
PremiumThe Fly
Biogen price target raised to $231 from $222 at Morgan Stanley
1M ago
BIIB
Biogen price target raised to $251 from $237 at H.C. Wainwright
PremiumThe Fly
Biogen price target raised to $251 from $237 at H.C. Wainwright
1M ago
BIIB
Biogen price target lowered to $240 from $242 at RBC Capital
PremiumThe Fly
Biogen price target lowered to $240 from $242 at RBC Capital
1M ago
BIIB
Biogen price target raised to $240 from $225 at UBS
PremiumThe FlyBiogen price target raised to $240 from $225 at UBS
1M ago
BIIB
Biogen price target raised to $215 from $201 at Wedbush
Premium
The Fly
Biogen price target raised to $215 from $201 at Wedbush
1M ago
BIIB
Biogen price target raised to $219 from $215 at BofA
Premium
The Fly
Biogen price target raised to $219 from $215 at BofA
1M ago
BIIB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >